Sun Pharmaceutical Industries reported a 20% decline in net profit for Q1 FY26, but adjusted profits excluding exceptions ...

Choice Broking maintained an ‘ADD’ rating and a target price of Rs 1,825 on Sun Pharma. At the prevailing price, the target ...

Sun Pharma stock fell as much as 5.78% during trade so far to Rs 1,608 apiece on the NSE. It was trading 3.65% lower at Rs ...

Sun Pharmaceutical Industries reported a decline of 20 per cent in net profit at Rs. 2,278.63 crore during the first quarter of the current fiscal year, as compared to Rs. 2,835.62 crore during the ...

Sun Pharmaceutical's shares fell 5.7% to ₹1,608.30 after a 20% drop in net profit to ₹2,278 crore for Q1 FY26. Despite this, ...

Brokerages have recommended several stocks to buy today (August 1) for long-term gains. The top recommendations are- HUL, IGL, Sun Pharma and Ambuja Cement. Let's take a look at target price below: ...

Sun Pharma's Q1 net profit fell 20% YoY to Rs 2,279 crore, while adjusted net profit rose 6%. India market showed strong momentum. Leqselvi US launch announced.

Sun Pharmaceutical Industries reported a 20% decline in net profit for Q1 FY26, standing at ₹2,279 crore. The fall is ...

India’s largest drugmaker, which has posted steady mid-to-high single digit growth for the last eight consecutive quarters, ...

Sun Pharma's top management reassures no plans to shift manufacturing to US despite looming tariffs, strong Q1 performance.

Sun Pharmas earnings before interest, tax, depreciation and amortisation (EBITDA) rose to Rs 4,302 crore in Q1 FY26, up from ...

New Delhi: Sun Pharmaceutical Industries on Thursday said its consolidated net profit declined 20 per cent year-on-year to Rs 2,279 crore for the first quarter ended June 30, 2025. The Mumbai-based ...